Letter from Leadership at Alexion and Amolyt

July 16, 2024

To our Patient Advocacy Community,

 

We are excited to share with you that AstraZeneca announced today the successful completion of the acquisition of Amolyt Pharma. The acquisition bolsters the Alexion, AstraZeneca Rare Disease pipeline and expands on its bone metabolism franchise with the addition of eneboparatide (AZP-3601), designed to meet key therapeutic goals for hypoparathyroidism.

 

For those of you who are not familiar, Alexion has been a pioneering leader in rare disease for more than three decades and has a deep commitment to partnering with patients. Together with Amolyt’s deep expertise in hypoparathyroidism, Alexion is uniquely positioned to drive the late-stage development and potential global commercialisation of eneboparatide. This is a great coming together.

 

We are very excited about this opportunity to work together for the Hypopara patient community. We are committed to listening to and learning from you as the foundation of our partnership, and we look forward to supporting you as you continue advocating on behalf of this community.

 

Thank you for your continuous engagement and support. We would be happy to answer any question you might have in the coming days. You can reach us at [email protected].

 

 

Best wishes,

 

Wendy                                           and            Blandine

 

Wendy Erler                                                                                            Blandine Weiss

VP Patient Experience                                                                          Director Medical Affairs

Alexion Astra Zeneca Rare Disease                                                       Amolyt Pharma

 

Back to News